



11-13  
OCTOBER  
2024

INTERCONTINENTAL,  
FESTIVAL CITY, DUBAI  
UNITED ARAB EMIRATES

BREAST CANCER SESSION



12 OCTOBER 2024  
(SATURDAY)



08:30 - 17:00 HRS  
UAE TIME



IN-PERSON



AL RAS 3

In conjunction with



In collaboration with



Supported by




Congress Secretariat




cancercongress.ae

**MEET OUR FACULTY**

**SESSION CHAIRPERSONS**



**TBA**



**TBA**

**MEET OUR EXPERTS**



**GIUSEPPE CURIGLIANO**  
Istituto Europeo di Oncologia and  
University of Milano  
Italy



**HAMDY ABDULAZIM**  
Cairo University  
Egypt



**JAVIER CORTES**  
International Breast Cancer Center (IBCC)  
Spain



**LEE SOO CHIN**  
National University Cancer Institute  
Singapore



**MARK VERRILL**  
Northern Centre for Cancer Care  
United Kingdom



**MAROUN EL KHOURY**  
American Hospital - Dubai  
UAE

# BREAST CANCER SESSION



**MOHSEN MOKHTAR**  
Cairo University  
Egypt



**NITA NAIR**  
Apollo Cancer Centre  
India



**NITESH ROHATGI**  
Fortis Memorial Research Institute  
India



**SHANU MODI**  
Memorial Sloan Kettering Cancer Center  
USA



**SHONA NAG**  
Sahyadri Group of Hospitals  
India



**12 OCTOBER 2024**  
(SATURDAY)



**08:30 - 17:00HRS**  
UAE TIME



**IN-PERSON**



**AL RAS 3**

## SESSION 1: Innovations In Breast Cancer Chairperson: TBA | TBA

08:30 - 8:40	<b>Opening Remarks</b> <b>Shaheenah Dawood, UAE</b>
08:40 - 09:00	ESMO / ASCO 2024: What Worked and What Did Not? <b>Lee Soo Chin, Singapore</b>
09:00 - 09:15	<b>Featured Talk</b>
09:15 - 09:30	HER2 Low: Where are we in 2024? <b>Giuseppe Curigliano, Italy</b>
09:30 - 09:45	Building Patients Profiles for DB04 and DB06 <b>Shanu Modi, USA</b>
09:45 - 10:00	<b>Featured Talk</b>
10:00 - 10:20	Round Table Discussion: Challenging Questions and Cases in the HER2 Low Realm! <b>Moderator:</b> <b>Panel:</b> <b>Giuseppe Curigliano, Italy   Shanu Modi, USA   Mohsen Mokhtar, Egypt</b>
10:20 - 10:30	Q & A
10:30 - 10:50	Coffee Break

## SESSION 2: Therapeutic Options in the Metastatic Setting: Where are we in 2024? Chairperson: TBA | TBA

10:50 - 11:10	<b>Featured Talk</b>
11:10 - 11:25	Maximizing Endocrine Therapy Options in the Metastatic Setting <b>Hamdy Azim, Egypt</b>
11:25 - 11:40	How to Optimize Use of ADCs in the HR+ve/HER2-ve Setting: Is there an Optimal Sequence? <b>Javier Cortes, Spain</b>
11:40 - 11:55	<b>Featured Talk</b>
11:55 - 12:10	<b>Featured Talk</b>

# BREAST CANCER SESSION

12:10 - 12:25	How I Approach a Patient with Metastatic Triple Negative Breast Cancer: Perspectives for the Community Oncologist <b>Nitesh Rohatgi, India</b>
12:25 - 12:40	A Future Look at the Therapeutic Landscape of Metastatic Disease: A Sneak Peek at Novel Agents <b>Lee Soo Chin, Singapore</b>
12:25 - 12:45	Round Table Discussion: Linking Patient Profiles to Therapeutic Options <b>Moderator: Mohsen Mokhtar, Egypt</b> <b>Panel: Giuseppe Curigliano, Italy   Shanu Modi, USA   Hamdy Azim, Egypt</b>
12:45 - 13:00	<b>Featured Talk</b>
13:00 - 13:10	Q & A
13:10 - 14:10	Lunch Break

## SESSION 3: Therapeutic Options in the Early Stage Setting: Where are We in 2024? Chairperson: TBA | TBA

14:10 - 14:25	<b>Featured Talk</b>
14:25 - 14:40	Optimizing Adjuvant Endocrine Therapy: 5 years, 7 years or 10 years <b>Javier Cortes, Spain</b>
14:40 - 14:55	Who should get an Adjuvant CDK4/6i and why? <b>Shona Nag, India</b>
14:55 - 15:10	<b>Featured Talk</b>
15:10 - 15:25	Does Everyone need an ALND Post Neoadjuvant Therapy? <b>Nita Nair, India</b>
15:25 - 15:40	<b>Featured Talk</b>
15:40 - 16:05	Round Table Discussion: Navigating the Muddy Waters of Adjuvant Therapy <b>Moderator: Shanu Modi, USA</b> <b>Panel: Lee Soo Chin, Singapore   Javier Cortes, Spain   Mark Verrill, UK</b>
16:05 - 16:15	Q & A
16:15	<b>Closing Remarks</b>